Expanding the CAR Platform
HGEN005 has the cutting-edge potential to demonstrate superior efficacy to treat eosinophilic diseases due to its selectivity to hit the right target and its penetration to deplete eosinophils in tissue. A major limitation of current eosinophil-targeted therapies is incomplete depletion of tissue eosinophils and/or lack of cell selectivity.
Eosinophils are a type of white blood cell. If too many are produced in the body, chronic inflammation and tissue and organ damage may result. The origin and development of eosinophilic disorders is mostly due to eosinophils infiltrating tissue.
EMR1 is expressed exclusively on eosinophils, making it an ideal potential target for the treatment of eosinophilic disorders. Regardless of the eosinophilic disorder, mature eosinophils express EMR1 in tissue, blood and bone marrow in patients with eosinophilia.
In pre-clinical work, eosinophil killing was enhanced in the presence of HGEN005 and immune effector cells. Evidence shows HGEN005’s anti-EMR1 activity could selectively target and safely eliminate eosinophils in vivo in a primate model.
Thus, HGEN005 offers promise in a range of eosinophil-driven diseases, such as:
- eosinophilic leukemia
- eosinophilic asthma
- eosinophilic esophagitis
- eosinophilic granulomatosis with polyangiitis.
HGEN005 is another plank in our growing platform of CAR-T therapies. Because of its high selectivity, HGEN005 has significant potential incorporated into a CAR-T construct. Discussions are underway with a leading center in the U.S. to develop a series of CAR constructs based on HGEN005 and to explore further pre-clinical testing in eosinophilic leukemia, an orphan condition with significant unmet need.